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Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), causes the most human
deaths than any other diseases from a single infectious agent. Treatments are long and
costly and have many associated side effects. Intracellular bacilli are slow growing and dif-
ﬁcult to target, which is augmenting the emergence of multi-drug resistance. A hallmark
trait of TB is the formation of granulomas, chronic cellular aggregates, which limit bacte-
rial growth but provides a survival reservoir where bacilli may disseminate from. Targeting
intracellular Mtb is challenging, but nanomedicine may offer a solution. Nanomedicine is a
signiﬁcantly growing research area and offers the potential for speciﬁc disease targeting,
dosage reduction, and intracellular drug delivery. This review discusses the application of
the various forms of nanomedicine towards targeting of Mtb.
Tuberculosis
Tuberculosis (TB), caused by the bacillus Mycobacte-
rium tuberculosis (Mtb), remains a global crisis. The
World Health Organization states that TB kills 1.6 mil-
lion people annually, 10 million more develop the dis-
ease each year, and approximately one-quarter of the
world’s population are latently infected.(WHO, 2018a)
In September 2018, the ﬁrst-ever high-level meeting
on TB was held, where world leaders met at the United
Nations (UN) Heads of State General Assembly to ad-
dress the problems faced in eradicating the disease. It
is costly and very difﬁcult to treat, requiring multi-drug
therapy over long periods (6–24 months).(Tiberi et al.,
2018; WHO, 2018a) For drug-sensitive TB, the World
Health Organization guidelines recommend daily ad-
ministration of rifampicin (RIF), isoniazid (INH),
pyrazinamide (PZA), and ethambutol for 2 months,
followed by INH and RIF for a further 4 months.(WHO,
2018a) The development of anti-TB drugs lacks invest-
ment with only two new drugs, bedaquiline and
delamanid, being approved (for multi-drug-resistant
[MDR] TB) in the past 50 years.(Ferlazzo et al., 2018)
Poor therapy management and patient noncompliance
can lead to complications (such as MDR), and the ad-
verse reactions to anti-TB drugs can cause signiﬁcant
problems.
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The most common route of infection is the respira-
tory route whereby bacteria enter through aerosol
droplet nuclei (1–5 μm), passed from an individual in-
fected with pulmonary or laryngeal TB to a susceptible
individual through coughing and sneezing. Mtb viru-
lence is often deﬁned by its transmission and intracellu-
lar survival ability, which is complex and is yet to be
fully understood.(Simeone et al., 2015) It is established
that the pathogen can adapt, allowing it to avoid the
hostile environment of the phagosome, but how Mtb
achieves intracellular survival is not fully elucidated,
as the lysosome is a complex organelle, which holds
many different enzymes with the capability of
degrading many microorganisms.
The human immunodeﬁciency virus (HIV) causes AIDS
(acquired immunodeﬁciency syndrome) in humans.
There are an estimated 36.9 million people infected
with HIV,(UNAIDS, 2018) and owing to immunosuppres-
sion, these patients are highly susceptible to
contracting active TB and/or reactivation of latent TB
infection. Tuberculosis and HIV are among the leading
causes of mortality worldwide, and in 2017, there were
300,000 TB deaths among HIV-positive people.(WHO,
2018a; WHO, 2018b) Coinfection makes treatment very
problematic; for example, RIF induces the activity of
the CYP3A enzyme system in the liver, and this cyto-
chrome metabolizes most antiretroviral drugs and
therefore decreases the concentration of these drugs
in the blood.(Swaminathan and Narendran, 2008)
Following the UN TB meeting in 2018, which has
given a new boost to TB funding and a renewed interest
in anti-TB drug research, the aim of this review is to
highlight current work in the ﬁeld, the beneﬁts of
exploiting nanotechnology for targeted infectious dis-
ease research, and, ﬁnally, outline the potential to-
wards clinical trial development, which has yet to be
achieved for nano-therapeutic-focused TB treatment.
Nanomedicine
Nanotechnology holds great promise to improve human
health and is predicted to signiﬁcantly beneﬁt all hu-
man society.(Etheridge et al., 2013; Chang et al.,
2015; Saravanan et al., 2018) There has been a rapid
global growth of nanomedicine research in recent
years, demonstrated by a 280% increase in scientiﬁc ci-
tations for the term nanomedicine in the last 5 years,
and around a 7000% increase in the last 15 years
(SciFinder keyword search; nanomedicine [January
2019]). In commercial terms, nanomedicine represents
a signiﬁcant growth area with the global market growth
rate of 12.3% predicted to rise to $177.6bn between
2013 and 2019.(Transparency Market Research, 2018)
The ability to create nanoscaled materials has allowed
advancements in medicines, targeted drug delivery,
and diagnostic tools as well as offered a novel set of an-
timicrobial agents.(Byrne et al., 2011; McDonald et al.,
2013; Donnellan et al., 2015) There are many advan-
tages to using nano-formulations for therapeutic uses,
such as the possibility of lowering the drug dose admin-
istered to patients, thus causing fewer side effects and
possibly reducing treatment time. This is achieved
through improved targeting of the drug-bearing nano-
particle (NP) to the required target, therefore enhanc-
ing the drug concentration at speciﬁc sites while
decreasing delivery to nontarget sites.(Byrne et al.,
2011) Targeting (which can be active or passive) can
be achieved by modifying NP surfaces with polymers
and/or through bio-conjugation of antibodies and spe-
ciﬁc ligands. This can prevent NPs from binding with
nonspeciﬁc blood components and targets them to spe-
ciﬁc receptors.(McCarron et al., 2008; Kamaly et al.,
2012) This can also increase the blood circulation time
of nanomedicines, which may be achieved by reducing
the phagocytic clearance of a drug.(Kamaly et al.,
2012) Addition of the polymers, such as polyethylene
glycol, to the surface of NPs renders the NP hydrophilic.
This addition reduces reticuloendothelial system up-
take of NPs (e.g., the liver and spleen), thus allowing
it to stay in circulation longer.(Jokerst et al., 2011)
Polyethylene glycol is also reported to reduce the for-
mation of aggregates. Additionally, if drugs are encap-
sulated by NPs (e.g., liposomes), they can be
protected from enzymatic degradation (e.g., in the
blood), and this could also improve drug stability.
Nanocarriers can be designed to control drug release
(e.g., some carriers will only release drugs at a certain
pH) possibly further enhancing drug absorption at spe-
ciﬁc sites.
Nanoparticles have a large surface area relative to
their volume, and their size is comparable with that
of intracellular macromolecules and organelles such as
proteins and DNA. Their small size allows
nanomedicines to interact with targets both on cell sur-
faces and internally.(Navalakhe and Nandedkar, 2007)
Macrophages uptake and phagocytose smaller entities
more readily than do larger forms of the same mate-
rial.(Clift et al., 2008; Nasiruddin et al., 2017) There-
fore, if drugs are in the nano-form, this could be
advantageous in treating some diseases where bacteria
reside in immune cells (e.g., TB) or in cancer
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treatments, where it is reported that liposomes < 130
nm have a higher level of selectivity and tumor accu-
mulation over larger liposomes.(Meerovich et al.,
2008) This is a phenomenon of the “enhanced perme-
ability and retention” effect, another means of
targeting NPs to speciﬁc sites (size dependent), where
NPs direct drug away from sites with tight epithelial
junctions in the healthy vasculature and instead accu-
mulate in areas where fenestrations (gaps) exist follow-
ing new, abnormal tissue growth (i.e., tumors), thus
enhancing permeation. Retention occurs as lack of lym-
phatic drainage from tumors leads to poor removal of
NPs. Additionally, in the nano-form, drug bioavailability
can be increased owing to the relatively high surface
area available allowing for higher local concentration.
Nanotechnology has many applications within the
medical ﬁeld, but in the context of therapeutics, there
are three overarching nanomedicine types that will be
discussed herein: nanocarriers, polymer therapeutics,
and solid drug nanoparticles (SDNs) (Fig. 1).
Nanocarriers
The largest category of nanomedicine, in which nano-
scale materials act as vehicles to transport drugs that
are either encapsulated within the nanocarrier core or
adhered to the surface.(Torchilin, 2006) In both cases,
adherence of drug to the carrier is generally through
noncovalent attachment. There are several subcate-
gories of nanocarriers, summarized in Figure 1.
Nanoemulsions and solid lipid nanoparticles (SLNs) are
conceptually identical where in both cases, biologically
compatible lipids are used to solvate and encapsulate
hydrophobic drugs forming a lipid nanocarrier.(Müller
et al., 2000; Mehnert and Mäder, 2001; Date et al.,
2010; Gordillo-Galeano and Mora-Huertas, 2018; Tayeb
and Sainsbury, 2018) Surface stabilizers, such as amphi-
philic block copolymers (i.e., linear or branched chain
polymers, which incorporate both hydrophobic and hy-
drophilic sections to their structure) are incorporated
into the nanocarrier to provide colloidal stability. The
primary difference between nanoemulsions and SLNs
is the use of liquid or a solid core, respectively, with
the choice of lipid allowing for controlled release rates
of the encapsulated drug. Polymer NPs are similar;
however, they incorporate no lipid. Instead, hydropho-
bic drugs are encapsulated into a hydrophobic polymer
core, which forms through the collapsing and aggrega-
tion of hydrophobic polymer chain in aqueous solvent.
(El-Say and El-Sawy, 2017) The structure forms from
amphiphilic block copolymers, which entrap the hydro-
phobic drug upon self-assembly in aqueous media with
the hydrophilic segment of the polymer protruding
Figure 1. Schematic of the three overarching nanomedicine forms.
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from the surface into the aqueous solvent. The amphi-
philic polymers thus provide both the core and colloidal
stability. Provided that biologically safe polymers and
monomers are used, drugs are released through physio-
logical biodegradation of the polymer structure. Self-
assembled structures are common in nanocarrier de-
sign, with liposomes, niosomes, and polymer micelles
formed through the assembly of amphiphilic smaller
molecules to generate spherical structures, which en-
capsulate drugs. Both liposomes and niosomes are
vesicle-type structures formed through generation of
a liquid encapsulated within a lipid bilayer. Liposomes
are generally formed through use of phospholipids,
which consist of two hydrophobic fatty acid chains at-
tached to a hydrophilic phosphate group head.
(Torchilin, 2005; Allen and Cullis, 2013) In aqueous me-
dia, the molecules assemble to form a bilayer where
the hydrophobic parts of the molecule are protected
from the external aqueous environment. Thus, an
aqueous region is present in the center of the nonpolar
hydrophobic membrane. Niosomes are conceptually
identical; however, the key difference is the use of bio-
degradable nonionic surfactants to form the bilayer,
which are often relatively nontoxic, more stable, and
inexpensive when than are liposomes.(Kuotsu et al.,
2010; Ag Seleci et al., 2016) In both cases, single bi-
layer (unilamellar) or multiple bilayers (multilamellar)
structures can form with either hydrophobic or hydro-
philic drugs encapsulated in the membrane or the aque-
ous center, respectively. Polymer micelles form through
the self-assembly of amphiphilic block copolymers,
thus similar to polymer NPs; however, in this case, a
wet, ﬂexible core is formed as opposed to a
solid/semisolid core.(Ahmad et al., 2014; Karayianni
and Pispas, 2016) In polymer micelles, the amphiphilic
polymers arrange themselves, so the hydrophobic part
of the polymer sits in the center of the spherical struc-
ture where hydrophobic drugs will be encapsulated.
The hydrophilic, polar part of the polymer on the sur-
face in contact with the surrounding aqueous solvent
provides colloidal stability.
Polymer therapeutics
Drugs are delivered through the conjugation to a bio-
logically compatible polymer, which are cleaved and re-
leased upon delivery.(Duncan, 2003; Khandare and
Minko, 2006; Duncan, 2011; Seidi et al., 2018) Polymer
therapeutics include polymer–drug conjugates, where
molecular drugs are delivered; polymer–protein conju-
gates, where a therapeutic protein is delivered; and
polyplexes, which are formed through a DNA–polymer
complex. Polymer therapeutics are often referred to
as prodrugs, and although they lack particulate charac-
teristics and thus do not ﬁt with the conventional view
of nanoparticulate design, they are included in many
nanomedicine deﬁnitions owing to their size range of
around 2–100 nm and their physiological behavior. Drugs
are covalently attached to the polymer through a linker
and as such are not released until they encounter a spe-
ciﬁc biological trigger, thus preventing wide physiologi-
cal distribution. Cleavage is typically achieved using
pH-responsive polymers or through enzymatic cleavage
via disease-speciﬁc enzymes. The polymers serve sev-
eral purposes: they increase the overall drug molecular
weight, thus increasing its circulatory half-life; they
lower the rate of clearance, thus varying the biological
distribution of the drug; and they can incorporate func-
tionality to address issues such as active site targeting
or drug solubility. Multiple drug conjugates can be in-
corporated into the polymer for either direct or
sustained combinational drug delivery.
Solid drug nanoparticles
Solid drug nanoparticles are the simplest form of
nanomedicine, often referred to as nanosuspensions or
nanodispersions.(Rabinow, 2004; McDonald et al.,
2015) The NP is composed of the drug molecule itself
with surface-adsorbed stabilizers providing colloidal
stability (Fig. 1). Reduction in particle size through
SDN formulation increases the surface-to-volume ratio
of the drug particle, thus exposing greater drug content
with respect to the nonformulated, native drug, as il-
lustrated in Figure 2.
The drug molecules employed are predominantly hy-
drophobic with very low water solubility. There are two
main synthetic methods for SDN production: top-down
and bottom-up approaches.(Junghanns and Müller,
2008; Möschwitzer, 2013; Wais et al., 2016) Top-down
approaches are where larger particles are repeatedly
broken down into smaller participles until a size range
distribution of less than 1000 nm is achieved. Examples
include nano-milling or homogenization. Bottom-up ap-
proaches are where controlled crystallization or precip-
itation of dissolved drugs takes place. In both cases,
amphiphilic stabilizers are present, which adsorb onto
the surface of the SDN as they develop. The stabilizers
are either polymer or surfactants or a combination of
both. Colloidal stability is provided through either ste-
ric interaction (i.e., close-proximity repulsions be-
tween particles with long-chain polymer stabilizers) or
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electrostatic interactions (i.e., electrostatic repulsion
of similarly charged particles bearing cationic/anionic
polymers or surfactants). Drug release is achieved as
SDNs ultimately dissolve in vivo, with dissolution rates
varied owing to SDN composition. The aggregated drug
at the core of the SDN can either be crystalline or amor-
phous. Crystalline SDNs (often referred to as
nanocrystals) are generally slower to dissolve than are
amorphous SDNs; however, they may offer greater ad-
vantages in increasing drug circulatory half-life as well
as longer-term drug product storage.
Nanomedicine and tuberculosis
Delivering an effective concentration of anti-TB drugs
to sites where Mtb resides in the immune cells, deep
within the lungs, is a huge feat, as often drugs dissolve
rapidly and are absorbed by the blood.(Mizoe et al.,
2008) Granulomas are clusters of Mtb-infected macro-
phages surrounded by many immune cells, fatty acids,
and cholesterol, securing Mtb. Their function is to lo-
calize and contain the infection, preventing both its
growth and replication due to the acidic conditions with
low oxygen availability, but they are unable to destroy
all bacilli or prevent bacilli from generating energy.
(Smith, 2003; Pieters, 2008; Ehlers and Schaible,
2012) Granuloma formation is a hallmark trait of Mtb
infection (particularly in latent TB infection) and plays
a pivotal role in immune-pathogenesis, where in 10%
of cases bacilli from granulomas will escape and go on
to cause active disease.(Silva Miranda et al., 2012)
These structures are poorly vascularized,(Grobler
et al., 2016) and therefore, it is very difﬁcult to target
drugs to these high-content bacilli constructs. Cells
take up molecules/particles through phagocytosis, en-
docytosis, and pinocytosis. By engulﬁng NPs, particu-
larly in the case of macrophages where Mtb resides,
the particles may be colocalized with the pathogen.
This would allow for very accurate targeting, for both
antimicrobial NPs and drug delivery. Furthermore, it is
accepted that smaller NPs are efﬁcient at crossing
epithelial barriers following oral administration, hence
the branching of nanotechnology into TB research.
(Hussain et al., 2001) As such, nanomedicine has led
to an original path of research undertaken within the
therapeutic ﬁeld of TB.
Literature on using nanomedicines to target TB is
predominantly based on the use of polymers or lipo-
somes with ﬁrst-line drugs RIF or INH.(Pandey et al.,
2003; Pandey and Khuller, 2005; Pandey and Khuller,
2006; Ohashi et al., 2009; Hirota et al., 2010;
Aboutaleb et al., 2012; Raj et al., 2012; Chuan et al.,
2013; Dube et al., 2013; Vieira et al., 2017; Hakkimane
et al., 2018) Studies have highlighted the possibilities
of encapsulating anti-TB drugs within biodegradable
polymer NPs, thus increasing the concentration of drugs
at speciﬁc sites (e.g., infected macrophages) through
targeting. NPs containing anti-TB drugs are usually
made from biodegradable materials (e.g., alginate or
solid lipids), and most TB research focuses on the use
of poly-lactic-co-glycolic acid (PLGA) synthetic poly-
mers.(Gelperina et al., 2005; Ohashi et al., 2009; Sung
et al., 2009; Hirota et al., 2010; Onoshita et al., 2010;
Kalluru et al., 2013)
Hirota et al. carried out a study to determine the up-
take and cytotoxicity of PLGA microspheres (MSs)
loaded with RIF on an NR8383 cell line derived from
rat alveolar macrophages.(Hirota et al., 2010) It was
determined that RIF PLGA-MS had little/no cytotoxicity
against the NR8383 cells and were readily engulfed, sig-
niﬁcantly more than when compared with RIF as an
aqueous, native drug. Additionally, they reported that
high concentrations of RIF were detected within
phagosomes, suggesting that RIF entrapped in PLGA-
MS can enter membranes of macrophages (probably
through phagocytosis) more readily that can native
RIF. NR8383 cells were then infected with Mycobacte-
rium bovis Bacillus Calmette-Guérin (BCG) and exposed
to the RIF PLGA-MS. The RIF PLGA-MS was found to be
bactericidal against intracellular Mycobacterium bovis
BCG, signiﬁcantly more so than native RIF at both
Figure 2. Representation of solid drug nanoparticles (SDNs) compared with conventional drug (image not to scale) illustrating the large
surface area and surface-to-volume ratio.
Nanomedicine for TB treatment Samantha Donnellan and Marco Giardiello
2019 | Volume 4 | Issue 3 |
Page 80
concentrations tested (0.25 and 2.50 μg/mL) over a pe-
riod of 7 days.(Hirota et al., 2010) Sung et al. formu-
lated RIF-encapsulated PLGA NPs with aerosol delivery
directly into the lungs. They found the RIF concentra-
tion in the lungs over time was signiﬁcantly improved
when compared with native drug.(Sung et al., 2009)
Comparing RIF administered via a nanocarrier to a na-
tive solution in an in vitro setting offers encouraging re-
sults to go forward to animal and human trials. An
important factor to consider is the delivery means, that
is, whether directly into the airways (e.g., nebulizer) or
through a systemic route. The advantages of a more
targeted drug delivery for Mtb infections are numerous,
especially if it can allow for the lowering of dosing.
Vieira et al. created nanostructured lipid carriers
(NLCs) as nanocarriers of RIF for selective delivery.
(Vieira et al., 2017) To increase selectivity to macro-
phages, the NLCs were coated with mannose(Jain
et al., 2010) to target macrophage sugar receptors,
and they were evaluated for cellular uptake and their
impact on cell viability. The authors treated bone
marrow-derived macrophages (BMDMs) with
mannosylated RIF NLCs, RIF NLCs, and native RIF drug.
(Vieira et al., 2017) They followed cellular uptake using
ﬂuorescence microscopy and then quantiﬁed using ﬂow
cytometry. The mannose-coated RIF NLCs displayed a
14.5-fold increase in cellular uptake, which is encour-
aging but also highlights the power of targeting. Next,
the authors infected bone BMDMs with Mycobacterium
avium strain 2447 and treated them with mannosylated
RIF NLCs, RIF NLCs, and native RIF. At three time points
(0, 1, and 7 days), cells were lysed and bacteria suspen-
sions collected. Colonies were counted after a further 7
days’ incubation. Mannose-coated NLCs were reported
to be more successful in decreasing the growth of intra-
cellular M. avium strain 2447 than are controls. Finally,
the authors report that NLCs containing RIF drug exhib-
ited lower levels of cytotoxicity to BMDMs than did NLCs
with no drug and account this to the surface charge
of the NPs; however, the inclusion of the mannose
coating onto RIF NLCs did reduce cell viability.(Vieira
et al., 2017)
Hakkimane et al. prepared nano-formulations of
PLGA NPs loaded with RIF and IH2 (INH modiﬁed into
INH benz-hydrazone).(Hakkimane et al., 2018) The
characterization of the NPs shape and morphology was
analyzed using Scanning Electron Microscopy (SEM),
and Transmission Electron Microscopy (TEM) was
employed to visualize the encapsulation of drugs inside
the NPs. Reversed-phase High Performance Liquid
Chromatography (HPLC) was used to calculate the ex-
act amount of drug encapsulated, and NP stability tests
using dynamic light scattering were undertaken at dif-
ferent pH levels.(Hakkimane et al., 2018) Dynamic light
scattering measures hydrodynamic diameter, the size
of primary particles if dispersed, or agglomerates along
with the shell of ions/water molecules associated with
the surface, by measuring the scattered light that
passes through a solution. The zeta potential, a mea-
sure of the charge carried by NPs when suspended in
an aqueous environment, gives an indication of the sta-
bility of NPs in a solution. Polydispersity index (a mea-
sure of size variation) suggested the NPs were stable
and nonagglomerated, and drug release was described
as slow and steady following an initial burst phase.
Drugs encapsulated in NPs were found to be more stable
at different pH levels than were free, native drug. After
24 h, 70% (pH 4.5) and 50% of RIF had degraded (pH
7.4), whereas when encapsulated, drug was released
in a profoundly slower, sustained process over a period
of days.(Hakkimane et al., 2018) Mycobacterial suscep-
tibility tests were carried out using the traditional
MGIT™ system(Tortoli et al., 1999) against the Mtb lab-
oratory strain H37Rv. As growing Mtb utilize oxygen,
the MGIT™ 960 system records the level of oxygen de-
pletion via ﬂuorescence readings, thus indicating both
mycobacterial presence and growth. Comparing RIF-
loaded PLGA NPs with native RIF drug, the authors re-
port that at a concentration of 0.70 μg/mL, H37Rv de-
veloped resistance to native RIF but remained
sensitive to RIF PLGA NPs, in which 100% inhibited ba-
cilli growth.(Hakkimane et al., 2018)
Aboutaleb et al. created RIF-loaded solid lipid NPs
(SLNs [NPs with a solid hydrophobic core coated with
a phospholipid monolayer]) for intravenous administra-
tion.(Aboutaleb et al., 2012) The aim was to create
spherical, stable RIF SLNs < 100 nm in diameter. They
found that RIF was released over a 120-h period
in vitro in a biphasic pattern when in SLN form, thus in-
dicating that the drug release was controlled and did
not occur instantaneously. The antimycobacterial prop-
erties of the SLNs were tested against a surrogate strain
of Mycobacterium fortuitum in an extracellular envi-
ronment, and results show an eightfold higher efﬁcacy
at inhibiting growth when delivered in the SLNs com-
pared with native RIF solution. Controlled release could
offer the potential to lowering dosages.
Dube et al. have designed a 1,3-β-glucan (Glu) func-
tionalized chitosan shell (CS), PLGA core NPs loaded
with RIF drug (Glu–CS–PLGA + RIF) with the aim of both
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stimulating some antimicrobial responses that Mtb sup-
press within the host macrophage (e.g., the suppression
of reactive oxygen species [ROS]) and delivering RIF in-
tracellularly.(Dube et al., 2013) The spherical Glu–CS–
PLGA + RIF NPs created were approximately 280 nm in
size. With the use of human alveolar-like-macrophages,
NP uptake was achieved through incubation (6 h) and
conﬁrmed by confocal microscopy. Cytotoxicity testing
proved no signiﬁcant change in macrophage viability
when incubated with the NPs (although there was great
variation in the data).(Dube et al., 2013) The focus of
this work was on Mtb’s ability to prevent the host cell
(macrophage) from producing bactericidal ROS, reac-
tive nitrogen species (RNS), and pro-inﬂammatory cyto-
kines (e.g., IL-12 and IFN-γ). This suppression aids in
Mtb’s intracellular survival. In the design of Glu–CS–
PLGA + RIF NPs, 1,3-β-glucan was selected as it can in-
teract with Dectin-1 macrophage surface receptors,
which promote both pro-inﬂammatory cytokine produc-
tion and ROS/RNS generation and also enhance the pro-
cess of phagocytosis.(Dube et al., 2013) Results suggest
that CS–PLGA + RIF NPs successfully increased the anti-
microbial activities of macrophages; TNF-α, IFN-γ, and
IL-12 secretion was all enhanced by the NPs. Interest-
ingly, it was reported that RIF could be delivered at a
concentration four times higher than the mean concen-
tration into macrophages when delivered as an NP con-
struct rather than as a free RIF solution (in vitro);
however, the efﬁcacy of the drug in this NP formulation
is not known as no tests withMtb-infected macrophages
were carried out.(Dube et al., 2013)
In another study, Edagwa et al. demonstrated that
PLGA NPs encapsulate RIF and a modiﬁed INH drug
(INHP), localized in subcellular organelles within
phagosomes in monocyte-derived macrophages
(MDMs).(Edagwa et al., 2014) Results displayed confo-
cal microscopy images of PLGA RIF and INHP in
endosomal compartments. To determine whether these
NPs were trafﬁcked to the same compartment as
mycobacteria, the MDMs were infected with Mycobac-
terium smegmatis and then treated with the NPs. Imag-
ing suggested that colocalization also occurred for the
particles and mycobacteria, within the MDM cells.
(Edagwa et al., 2014) To assess their antimycobacterial
activities, MDMs were exposed to RIF PLGAs (loaded
with approximately 10% drug) and INHP PLGAs (loaded
with approximately 5% drug) for 24 h; then MDMs were
infected with M. smegmatis for 1–10 days. The same ex-
periment was carried out for RIF and INHP in native
forms. Comparing the results between the two types,
the PLGA NPs exerted over 1.3-fold greater toxicity af-
ter 1-day incubation with M. smegmatis at 300 μm.
(Edagwa et al., 2014) It was found that when MDMs
were infected with mycobacteria following 10 days of
exposure to the PLGAs or native drugs, the PLGA NPs
inhibited mycobacterial growth by 50%, whereas the
native drugs had no effect on mycobacterial growth in-
tracellularly. This suggested that in the nano-form,
drugs are retained for extended periods inside macro-
phage cells. It must be noted, however, that this was
a somewhat unorthodox means of measuring
antimycobacterial activity, as the macrophage cells
were ﬁrst treated with the drug (in both nano-forms
and native forms) before being infected with
mycobacteria. It is unclear whether this is a means to
prevent infection rather than clearing an infection.
Overall, however, these results were encouraging from
a nanomedicine perspective. With published reports
demonstrating PLGA NPs carrying anti-TB drugs being
engulfed by macrophages, the possibility of targeting
granulomas has begun to be investigated. Granulomas
harbor mycobacteria, which could cause reactivation
to a diseased state or lead to the development of MDR
TB. Grobler et al. have reported that delivering NPs
to granulomas is possible.(Grobler et al., 2016) With
the use of a colloidal Pheroids (NPs with oil, gas, and
water phases that are ﬁlled with RIF [dissimilar to
PLGAs]) and an in vitro granuloma model, it was possi-
ble to target NPs to the macrophages. Pheroids are a
patented drug delivery system, with the ability to con-
trol the rate of drug clearance and offer protection to
drugs (e.g., from enzyme degradation) in vivo.(Steyn
et al., 2010) The analytical model presented by Grobler
et al. demonstrates that when RIF was delivered using
Pheroids, when compared with native RIF, there was a
signiﬁcantly higher concentration of RIF in the macro-
phages than in the blood (of 16 patients following their
fourth daily dose of drug).(Grobler et al., 2016) Addi-
tionally, using the delivery system, higher drug concen-
trations were measured at several positions in the
granuloma model when compared with the native RIF.
This work correlated nicely with the previous reports;
when RIF was administered in a nano-formulation
(loaded on PLGAs, SLNs, or packaged in Pheroids), com-
pared with a solution of native RIF, a higher concentra-
tion of drug reached the desired site.
We have developed SDNs of ﬁrst-line drugs RIF, INH,
ethambutol, and PZA.(Donnellan et al., 2017) The work
was conducted following our same developmental pro-
cedure, which led human clinical trials of SDN-
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formulated HIV antiretroviral drugs efavirenz(Mcdonald
et al., 2014) and lopinavir(Giardiello et al., 2016)
(EudraCT number 2013-004913-41). We screened the
efﬁcacy of the NPs against a reporter strain of M. avium
subsp. paratuberculosis (Map K10/GFP(Harris et al.,
2002)). We found that RIF SDNs were 50-fold more efﬁ-
cacious, as evidenced by a reduced IC50 value (0.02
compared with 1.06 μg/mL) than was native drug. Addi-
tionally, RIF SDNs had a faster kill rate against Map than
had native RIF.(Donnellan et al., 2017) Next, we
treated Map-infected macrophage-like cells (J774s)
with SDNs and imaged uptake to determine if SDNs
could be trafﬁcked to mycobacteria residing in macro-
phages (Fig. 3). Solid drug nanoparticles and
mycobacteria were found to be colocalizing within the
cells. Additionally, we reported that the intracellular
kill rate of the SDNs was more effective than that of
the native drug.(Donnellan et al., 2017)
Conclusions
The intracellular delivery of drugs remains a challenge
to the TB research community, especially for treating
the latent form of the disease, where bacilli reside
within granulomas. A major problem in TB treatment
is patient noncompliance, attributed to the lengthy
treatment periods and daily, multi-drug dosing. If
nanomedicines could aid in lowering drug dosages and
treatment periods, this could help reduce this problem.
Tuberculosis and HIV are closely associated, with TB be-
ing the most common cause of AIDS-related death;
therefore, treatments need to be developed to con-
sider coinfected patients. With a clinical trial for SDN-
formulated HIV therapy underway, this ﬁeld should also
include TB treatment, as evidenced by all the in vitro
studies outlined within. Nanomedicine is a rapidly
expanding area and could provide multiple research av-
enues towards improving treatment outcomes, reduc-
ing drug dosing, and improving targeting. Currently,
there are 50 clinically FDA (United States Food and Drug
Administration)-approved nanomedicines. Of the 50 in
clinical use, the most commonly used NP types are poly-
mer (34%), nanocrystal (30%), and liposome (20%).
When searching the term “nano” on ClinicalTrials.gov,
a further 66 clinical trials included are listed as
“recruiting” or “active” (as of January 2019). However,
none of the approved nanomedicines or upcoming trials
are aimed at TB treatment. There are numerous exam-
ples, however, of nanomedicine strategies utilizing
polymer NPs, liposomal/noisomal delivery systems,
and SLNs towards TB therapy, each showing good pre-
clinical data and thus presenting themselves as good
candidates for potential clinical studies.(Madeeha
et al., 2016; Nasiruddin et al., 2017)
Overall, the pipeline for TB drug development is not as
stagnant as it once was. There are more avenues and
exciting areas being explored with nanotechnology being
a driving force behind this. As evidenced here, there is
plenty of preclinical work within the TB/nanoﬁeld being
undertaken, but this needs to be fast-tracked and taken
to the clinic. Additionally, a further understanding of
how drugs penetrate the lung cavities would be beneﬁ-
cial and may allow a more tailored, nano-based regime
to be designed, to exploit the unique properties of
nanomedicines. Nanomedicine may also offer relief to
the ﬁnancial burden in TB drug development. For exam-
ple, by using SDNs of ﬁrst-line antibiotics, it is exploiting
existing FDA-approved pharmaceutical ingredients,
therefore saving time and the inordinate cost involved
in novel drug development and testing.
This review aimed to highlight the use of nanotech-
nology towards the cellular targeting of drugs towards
TB therapy, as well as the signiﬁcant growth and range
of nanomedicine strategies, not all of which have been
adopted by TB research. These must be addressed and
accelerated to meet the UN target of hastening prog-
ress towards the eradication of TB.
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